Another study is adding to a growing body of literature that suggests convalescent plasma from recovered patients with Covid-19 does not prevent further Covid-19 progression in at-risk people who visit the emergency room.
The U.S. National Institutes of Health (NIH) halted a trial of convalescent blood plasma in the treatment of patients with mild-to-moderate Covid-19 symptoms as it was unlikely to benefit this group.
A study published in JAMA suggests that treatment with vitamin C, in addition to thiamine and hydrocortisone, does not improve treatment outcomes in hospitalized patients with sepsis.
The new Covid-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line of vaccines, according to scientists.
A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.
Using blood plasma from Covid-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released from a clinical trial in Argentina.
The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health official said.
Heron Therapeutics Inc.’s New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration for HTX-011, an investigational agent for the management of postoperative pain.
Researchers called for more research into using blood from recovered Covid-19 patients – or so-called convalescent plasma – as a potential treatment, after a small trial of hospitalized patients in India found it was of no benefit.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes a higher complication rate with Covid-19 versus the flu.